Dendritic cells and melanoma
Keywords:
dendritic cells, vaccination, immunotherapy, melanomaAbstract
The survival of patients with disseminated melanoma has not improved despite years of research. The immune eradication of tumor cells or inducing a state of tolerance depends on a complex interaction between melanoma cells and several cell types of the immune system including dendritic cells, effector T cells and regulatory T cells. Dendritic cells are responsible for the generation of tumour-specific immunity through the processing and presentation of tumour-associated antigens. The number and function of dendritic cells can be altered in different neoplasias including melanoma. Understanding the nature and functions of this cell population has allowed the development of vaccines based on dendritic cells for different diseases, and melanoma is the most studied entity in this field.
Author Biographies
Mónica Lorena Cárdenas
Médica, residente de tercer año de Dermatología, Facultad de Medicina, Universidad del Valle, Cali, Colombia
Lucy García
Médica dermatóloga, M.Sc.; docente de Dermatología, Facultad de Medicina, Universidad del Valle, Cali, Colombia
References
1. Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC Jr, Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatol. 2008;3:569-85.
2. Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O, et al. Long-term protective effect of mature DCLAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res. 2007;13:3825-30.
3. Li YP, Latger-Canard V, Marchal L, Li N, Ou-Yang JP, Stoltz JF. The regulatory role of dendritic cells in the immune tolerance. Biomed Mater Eng. 2006;16:S163-70.
4. Blanco P, Palucka A, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008;19:41-52.
5. McGovern VJ. Spontaneous regression of melanoma. Pathology. 1975;7:91-9.
6. Tuettenberg A, Schmitt E, Knop J, Jonuleit H. Dendritic cellbased immunotherapy of malignant melanoma: success and limitations. J Dtsch Dermatol Ges. 2007;5:190-6.
7. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-32.
8. Wu L, Liu YJ . Development of dendritic-cell lineages. Immunity. 2007;26:741-50. 9. Sato K, Fujita S. Dendrititc cells-nature and classification. Allergol Int. 2007;56:183-91.
10. Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, et al. Dendritic cell subsets in health and disease. Immunol Rev. 2007;219:118-42.
11. Ishikawa F, Niiro H, Iino H, Yoshida S, Saito N, Onohara S, et al. The developmental program of human dendritic cells is operated independently of conventional myeloid and lymphoid pathways. Blood. 2007;110:3591-660.
12. Lebre MC, Tak PP. Dendritic cell subsets: their roles in rheumatoid arthritis. Acta Reumatol Port. 2008;33:35-45.
13. Steinman R. Dendritric cells: Understanding immunogenicity. Eur J Immunol. 2007;37:s5360
14. Huang Q, Liu D, Majewski P, Schulte LC, Korn JM, Young RA, et al. The plasticity of dendritic cell responses to pathogens and their components. Science. 2001;294:870-5.
15. Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol. 2007;7:929-41.
16. Joffre O, Nolte MA, Sporri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev. 2009;227:234-47.
17. Sada-Ovalle I, Torre L, Jiménez M, Martínez S, Zenteno E, Lascurain R. La vía de CD1 y la activación de células T NK hacia los antígenos glicolipídicos de Mycobacterium tuberculosis. Gac Méd Méx. 2005;141:35-41.
18. Polak MA, Borthwick NJ, Jager MJ, Cree IA. Melanoma vaccines: The problems of local immune suppression. Human Immunol. 2009;70:331-9.
19. Elliot B, Scolyer RA, Suciu Stefan, Lebecque S, Rimoldi D, Gugerli O, et al. Long-term protective effect of mature DCLAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res. 2007;13:3825-30.
20. Lanadyl A, Kiss J, Somlal B, Fejos Z, Mohos A, Gaudi I, et al. Density of DC –LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a Sorong independent prognostic factor. Cancer Immunol Immunother. 2007;58:1459-89.
21. Charles J, Di Domizio J, Salameire D, Bendriss-Vermare N, Aspord C, Muhammad R, et al. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol. 2010;130:1646-56.
22. Llopiz D, Dotor J, Casares N, Bezunartea J, Díaz-Valdés N, Ruiz M, et al. Peptide inhibitors of transforming growth factor-beta enhance tehe efficacy of antitumor immunotherapy. Int J Cancer. 2009;125:2614-23.
23. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing t cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells J. Immunol. 2006;177:896-904.
24. Polak ME, Borthwick NJ, Gabriel PG, Johnson P, Higgins B, Hurren J, et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer. 2007;96:1879-87.
25. Polak ME, Johnson P, Di Palma S, Higgins B, Hurren J, Borthwick NJ, et al. Presence and maturity of dendritic cells in melanoma lymph node metastases. J Pathol. 2005;207:83-90.
26. Lesterhuis WJ, Aarntzen E, De Vries I, Schuurhuis D, Figdor C, Adema G, et al. Dendritic cell vaccines in melanoma: From promise to proof ? Crit Rev Oncol Hematol. 2008;66:118-34.
27. Palucka AK, Dhodapkar MV, Paczesny S, Burkeholder S, Wittkowski KM, Steinman RM, et al. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother. 2003;26:432-9.
28. Vilella R, Benítez D, Mila J, Lozano M, Vilana R, Pomes J, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother. 2004;53:651-8.
29. Bertholet S, Goldszmid R, Morrot A, Debrabant A, Afrin F, Collazo-Custodio C. Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo. J Immunol. 2006;177:3525-33.
30. Nasi ML, Lieberman P, Busam KJ, Prieto V, Panageas KS, Lewis JJ, et al. Intradermal injection of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines Cell Mol Ther. 1999;5:139-44.
31. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol. 2001;166:4254-9.
32. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, ThurnerSchuler B, Stuge TB, Paragnik L, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001;93:243-51.
33. Escobar A, López M, Serrano A, Ramírez M, Pérez C, Aguirre A, González R, et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol. 2005;142:555-68.
34. Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother. 2007;56:1513-37.
35. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004;10:475-80.
36. Ballestrero A, Boy D,Moran E, Cirmena G, Brossart P, Nencioni A. Immunotherapy with dendritic cells for cáncer. Adv Drug Deliv Rev. 2008; 60:173-83.
37. De Gruijl T, van den Eertwegh A, Pinedo H, Scheper R. Whole-cell cancer vaccination: from autologous to allogeneictumor- and dendritic cell-based vaccines. Cancer Immunol Immunother. 2008;57:1569-77.
38. El Marsafy S, Bagot M, Bensussan A, Mauviel A. Dendritic cells in the skin potential use for melanoma treatment. Pigment Cell Melanoma Res. 2009;22:30-41. Dendritic cells in the skin potential use for melanoma treatment. Pigment Cell Melanoma Res. 2009;22:30-41.
39. Aamtzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ. Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother. 2008;57:1559-68.
40. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
41. Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Reengineering dendritic cell-based anti-cancer vaccines. Immunol Rev. 2008;222:256-76.
42. Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di Nardo A, Kabigting FD, et al. Immunotherapy for melanoma: current status and perspectives. J Immunother. 2010;33:570-90.
43. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009;58:1-14.
44. Poehlein C, Rüttinger D, Ma J, Hu H, Urba W, Fox B. Immunotherapy for melanoma: the good, the bad, and the future. Curr Oncol Rep. 2005;7:383-92.
45. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563-70.
46. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitorderived dendritic cell vaccine. Cancer Res. 2001;61:6451-8.
47. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigenspecific CD8+ T cells in patients with melanoma. J Immunol. 2005;175:6169-76.
48. Met O, Wang M, Pedersen AE, Nissen MH, Buus S, Claesson MH. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett. 2006;231:247-56.
49. O’Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother. 2003;52:387-95.
50. O’Rourke MG, Johnson MK, Lanagan CM, See JL, O'Connor LE, Slater GJ, et al. Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res. 2007;17:316-22.
51. Jandus C, Speiser D, Romero P. Recent advances and hurdles in melanoma immunotherapy. Pigment Cell Melanoma Res. 2009;22:711-23.
2. Elliott B, Scolyer RA, Suciu S, Lebecque S, Rimoldi D, Gugerli O, et al. Long-term protective effect of mature DCLAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res. 2007;13:3825-30.
3. Li YP, Latger-Canard V, Marchal L, Li N, Ou-Yang JP, Stoltz JF. The regulatory role of dendritic cells in the immune tolerance. Biomed Mater Eng. 2006;16:S163-70.
4. Blanco P, Palucka A, Pascual V, Banchereau J. Dendritic cells and cytokines in human inflammatory and autoimmune diseases. Cytokine Growth Factor Rev. 2008;19:41-52.
5. McGovern VJ. Spontaneous regression of melanoma. Pathology. 1975;7:91-9.
6. Tuettenberg A, Schmitt E, Knop J, Jonuleit H. Dendritic cellbased immunotherapy of malignant melanoma: success and limitations. J Dtsch Dermatol Ges. 2007;5:190-6.
7. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-32.
8. Wu L, Liu YJ . Development of dendritic-cell lineages. Immunity. 2007;26:741-50. 9. Sato K, Fujita S. Dendrititc cells-nature and classification. Allergol Int. 2007;56:183-91.
10. Ueno H, Klechevsky E, Morita R, Aspord C, Cao T, Matsui T, et al. Dendritic cell subsets in health and disease. Immunol Rev. 2007;219:118-42.
11. Ishikawa F, Niiro H, Iino H, Yoshida S, Saito N, Onohara S, et al. The developmental program of human dendritic cells is operated independently of conventional myeloid and lymphoid pathways. Blood. 2007;110:3591-660.
12. Lebre MC, Tak PP. Dendritic cell subsets: their roles in rheumatoid arthritis. Acta Reumatol Port. 2008;33:35-45.
13. Steinman R. Dendritric cells: Understanding immunogenicity. Eur J Immunol. 2007;37:s5360
14. Huang Q, Liu D, Majewski P, Schulte LC, Korn JM, Young RA, et al. The plasticity of dendritic cell responses to pathogens and their components. Science. 2001;294:870-5.
15. Barral DC, Brenner MB. CD1 antigen presentation: how it works. Nat Rev Immunol. 2007;7:929-41.
16. Joffre O, Nolte MA, Sporri R, Reis e Sousa C. Inflammatory signals in dendritic cell activation and the induction of adaptive immunity. Immunol Rev. 2009;227:234-47.
17. Sada-Ovalle I, Torre L, Jiménez M, Martínez S, Zenteno E, Lascurain R. La vía de CD1 y la activación de células T NK hacia los antígenos glicolipídicos de Mycobacterium tuberculosis. Gac Méd Méx. 2005;141:35-41.
18. Polak MA, Borthwick NJ, Jager MJ, Cree IA. Melanoma vaccines: The problems of local immune suppression. Human Immunol. 2009;70:331-9.
19. Elliot B, Scolyer RA, Suciu Stefan, Lebecque S, Rimoldi D, Gugerli O, et al. Long-term protective effect of mature DCLAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin Cancer Res. 2007;13:3825-30.
20. Lanadyl A, Kiss J, Somlal B, Fejos Z, Mohos A, Gaudi I, et al. Density of DC –LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a Sorong independent prognostic factor. Cancer Immunol Immunother. 2007;58:1459-89.
21. Charles J, Di Domizio J, Salameire D, Bendriss-Vermare N, Aspord C, Muhammad R, et al. Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol. 2010;130:1646-56.
22. Llopiz D, Dotor J, Casares N, Bezunartea J, Díaz-Valdés N, Ruiz M, et al. Peptide inhibitors of transforming growth factor-beta enhance tehe efficacy of antitumor immunotherapy. Int J Cancer. 2009;125:2614-23.
23. Jarnicki AG, Lysaght J, Todryk S, Mills KH. Suppression of antitumor immunity by IL-10 and TGF-beta-producing t cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells J. Immunol. 2006;177:896-904.
24. Polak ME, Borthwick NJ, Gabriel PG, Johnson P, Higgins B, Hurren J, et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer. 2007;96:1879-87.
25. Polak ME, Johnson P, Di Palma S, Higgins B, Hurren J, Borthwick NJ, et al. Presence and maturity of dendritic cells in melanoma lymph node metastases. J Pathol. 2005;207:83-90.
26. Lesterhuis WJ, Aarntzen E, De Vries I, Schuurhuis D, Figdor C, Adema G, et al. Dendritic cell vaccines in melanoma: From promise to proof ? Crit Rev Oncol Hematol. 2008;66:118-34.
27. Palucka AK, Dhodapkar MV, Paczesny S, Burkeholder S, Wittkowski KM, Steinman RM, et al. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J Immunother. 2003;26:432-9.
28. Vilella R, Benítez D, Mila J, Lozano M, Vilana R, Pomes J, et al. Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate. Cancer Immunol Immunother. 2004;53:651-8.
29. Bertholet S, Goldszmid R, Morrot A, Debrabant A, Afrin F, Collazo-Custodio C. Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo. J Immunol. 2006;177:3525-33.
30. Nasi ML, Lieberman P, Busam KJ, Prieto V, Panageas KS, Lewis JJ, et al. Intradermal injection of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. Cytokines Cell Mol Ther. 1999;5:139-44.
31. Fong L, Brockstedt D, Benike C, Wu L, Engleman EG. Dendritic cells injected via different routes induce immunity in cancer patients. J Immunol. 2001;166:4254-9.
32. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, ThurnerSchuler B, Stuge TB, Paragnik L, et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer. 2001;93:243-51.
33. Escobar A, López M, Serrano A, Ramírez M, Pérez C, Aguirre A, González R, et al. Dendritic cell immunizations alone or combined with low doses of interleukin-2 induce specific immune responses in melanoma patients. Clin Exp Immunol. 2005;142:555-68.
34. Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother. 2007;56:1513-37.
35. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ. Dendritic cell immunotherapy: mapping the way. Nat Med. 2004;10:475-80.
36. Ballestrero A, Boy D,Moran E, Cirmena G, Brossart P, Nencioni A. Immunotherapy with dendritic cells for cáncer. Adv Drug Deliv Rev. 2008; 60:173-83.
37. De Gruijl T, van den Eertwegh A, Pinedo H, Scheper R. Whole-cell cancer vaccination: from autologous to allogeneictumor- and dendritic cell-based vaccines. Cancer Immunol Immunother. 2008;57:1569-77.
38. El Marsafy S, Bagot M, Bensussan A, Mauviel A. Dendritic cells in the skin potential use for melanoma treatment. Pigment Cell Melanoma Res. 2009;22:30-41. Dendritic cells in the skin potential use for melanoma treatment. Pigment Cell Melanoma Res. 2009;22:30-41.
39. Aamtzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ. Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother. 2008;57:1559-68.
40. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5:296-306.
41. Koski GK, Cohen PA, Roses RE, Xu S, Czerniecki BJ. Reengineering dendritic cell-based anti-cancer vaccines. Immunol Rev. 2008;222:256-76.
42. Alexandrescu DT, Ichim TE, Riordan NH, Marincola FM, Di Nardo A, Kabigting FD, et al. Immunotherapy for melanoma: current status and perspectives. J Immunother. 2010;33:570-90.
43. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother. 2009;58:1-14.
44. Poehlein C, Rüttinger D, Ma J, Hu H, Urba W, Fox B. Immunotherapy for melanoma: the good, the bad, and the future. Curr Oncol Rep. 2005;7:383-92.
45. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, et al. Dacarbazine (DTIC) versus vaccination with autologous peptide pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563-70.
46. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitorderived dendritic cell vaccine. Cancer Res. 2001;61:6451-8.
47. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigenspecific CD8+ T cells in patients with melanoma. J Immunol. 2005;175:6169-76.
48. Met O, Wang M, Pedersen AE, Nissen MH, Buus S, Claesson MH. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett. 2006;231:247-56.
49. O’Rourke MG, Johnson M, Lanagan C, See J, Yang J, Bell JR, et al. Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine. Cancer Immunol Immunother. 2003;52:387-95.
50. O’Rourke MG, Johnson MK, Lanagan CM, See JL, O'Connor LE, Slater GJ, et al. Dendritic cell immunotherapy for stage IV melanoma. Melanoma Res. 2007;17:316-22.
51. Jandus C, Speiser D, Romero P. Recent advances and hurdles in melanoma immunotherapy. Pigment Cell Melanoma Res. 2009;22:711-23.
How to Cite
1.
Cárdenas ML, García L. Dendritic cells and melanoma. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2019 Feb. 27 [cited 2026 Mar. 19];18(4):218-24. Available from: https://revistaasocoldermaorgco.biteca.online/index.php/asocolderma/article/view/337
Downloads
Download data is not yet available.
Downloads
Published
2019-02-27
How to Cite
1.
Cárdenas ML, García L. Dendritic cells and melanoma. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 2019 Feb. 27 [cited 2026 Mar. 19];18(4):218-24. Available from: https://revistaasocoldermaorgco.biteca.online/index.php/asocolderma/article/view/337
Issue
Section
Review Article
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
